Latest news
- Covalent Inhibitors in Drug Discovery: Current Applications
- Integration of Technologies in Drug Design: Molecular Dynamics and Deep Learning
- Announcement of Initial Listing on Tokyo Stock Exchange Growth Market
- Geometric Deep Learning for Structure-Based Drug Discovery
- Deep Learning Is Enabling Structure-Based Drug Design: Current Approaches
About
PRISM BIOLAB
MISSION:
PRISM BioLab is committed to maximizing the potential of its PepMetics® Technology, transforming the “undruggable” to “druggable” with the aim of finding cures for the incurable.
PRISM BioLab is a biotechnology company with PepMetics Technology, a proprietary drug discovery platform. PepMetics Molecules are designed to mimic α-helix or β-turn peptides using unique, stable scaffolds.
PepMetics
Technology
We synthesize like a small molecule, but our PepMetic Molecules act like peptides.
Peptide
MIMETICS
“PepMetics”®
LIBRARY
PRISM’s PepMetics Real Library includes 20,000+ compounds covering various amino acid sequences for screening. The PepMetics Library is used to generate hits for difficult targets.